H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Alumis (ALMS) to $19 from $26 and keeps a Buy rating on the shares after the company announced a merger with Acelyrin via an all-stock transaction. The firm updated the company’s model to account for the dilution.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS: